Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Company Deals Digital

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

Fineline Cube Apr 23, 2026
Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Fineline Cube Apr 23, 2026
Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Fineline Cube Apr 23, 2026
Company Medical Device

Cryofocus Medtech Receives NMPA Approval for Complete Cardiac Cryoablation System

Fineline Cube Dec 12, 2023

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Drug

Staidson Pharmaceutical Halts Clinical Trial for Hepatitis B Drug Due to Efficacy Concerns

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the cancellation...

Company Medical Device

Zylox-Tonbridge Medical Technology’s ZENFLOW T18 Receives NMPA Marketing Approval

Fineline Cube Dec 12, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a developer of nerve and peripheral vascular interventional devices based...

Company Drug

Skyline Therapeutics’ Gene Therapy SKG0201 for SMA Gets Green Light from China’s NMPA

Fineline Cube Dec 12, 2023

Skyline Therapeutics has received clinical trial approval from China’s National Medical Products Administration (NMPA) for...

Company Deals

Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate

Fineline Cube Dec 12, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark...

Company Deals

Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine

Fineline Cube Dec 12, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into...

Company Deals

Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China

Fineline Cube Dec 12, 2023

Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN)...

Policy / Regulatory

CDE Requests Feedback on 77th Batch of Chemical Generic Reference Preparations by December 20

Fineline Cube Dec 11, 2023

The Center for Drug Evaluation (CDE) is currently soliciting feedback on the 77th batch of...

Company Drug

Kelun-Biotech’s SKB264 NDA Accepted by NMPA for mTNBC, Poised to Be China’s First TROP2-targeted ADC

Fineline Cube Dec 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that its innovative drug development subsidiary, Sichuan...

Company Deals

Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform

Fineline Cube Dec 11, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies

Fineline Cube Dec 11, 2023

Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...

Company Deals

Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging

Fineline Cube Dec 11, 2023

Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT...

Company Drug

MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints

Fineline Cube Dec 11, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III...

Company Drug

Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer

Fineline Cube Dec 11, 2023

Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor...

Company

Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District

Fineline Cube Dec 11, 2023

Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event...

Company Drug

Keymed Biosciences’ Stapokibart Filing Accepted for Priority Review in China for Atopic Dermatitis

Fineline Cube Dec 8, 2023

Keymed Biosciences Inc. (HKG: 2162) has announced that its market filing for stapokibart (CM310), a...

Company Deals

Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin

Fineline Cube Dec 8, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement...

Company Drug

Pfizer and CStone Secure NMPA Approval for Sugemalimab, First PD-L1 Inhibitor for ESCC

Fineline Cube Dec 8, 2023

Pfizer (NYSE: PFE) and CStone Pharmaceuticals (HKG: 2616) have secured market approval from the National...

Company

Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030

Fineline Cube Dec 8, 2023

Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period,...

Company Deals

AbelZeta and AstraZeneca Team Up for Co-Development of GPC3-Targeted CAR-T Therapy

Fineline Cube Dec 8, 2023

AbelZeta Pharma Inc., a Sino-U.S. biotech firm based in Rockville, Maryland, and Shanghai, has announced...

Posts pagination

1 … 421 422 423 … 656

Recent updates

  • Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026
  • Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month
  • Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals
  • Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses
  • Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Company

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.